{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:36:51Z","timestamp":1783035411572,"version":"3.54.6"},"reference-count":58,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"5","license":[{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trans. Vis. Sci. Tech."],"published-print":{"date-parts":[[2023,5,23]]},"DOI":"10.1167\/tvst.12.5.17","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T14:31:19Z","timestamp":1684247479000},"page":"17","source":"Crossref","is-referenced-by-count":6,"title":["Aflibercept Suppression of Angiopoietin-2 in a Rabbit Retinal Vascular Hyperpermeability Model"],"prefix":"10.1167","volume":"12","author":[{"given":"Claudia","family":"Lange","sequence":"first","affiliation":[{"name":"Research & Development, Precision Medicine Markers, Bayer AG, Berlin, Germany"},{"name":"https:\/\/orcid.org\/0000-0001-7570-0261"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reimo","family":"Tetzner","sequence":"additional","affiliation":[{"name":"Research & Development, Biosample Operation Management and Assay Technologies, Bayer AG, Berlin, Germany"},{"name":"https:\/\/orcid.org\/0009-0000-9549-7731"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Strunz","sequence":"additional","affiliation":[{"name":"Research & Development, Biomedical Data Science II, Bayer AG, Wuppertal, Germany"},{"name":"https:\/\/orcid.org\/0000-0002-3744-9595"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay D.","family":"Rittenhouse","sequence":"additional","affiliation":[{"name":"Medical Affairs, Bayer Consumer Care AG, Basel, Switzerland"},{"name":"https:\/\/orcid.org\/0000-0001-7503-5759"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.preteyeres.2008.05.001","article-title":"Vascular endothelial growth factor in eye disease","volume":"27","author":"Penn","year":"2008","journal-title":"Prog Retin Eye Res"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"15313","DOI":"10.1038\/s41598-021-94500-1","article-title":"Gene expression profile of the murine ischemic retina and its response to aflibercept (VEGF-Trap)","volume":"11","author":"Rojo Arias","year":"2021","journal-title":"Sci Rep"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.preteyeres.2017.11.002","article-title":"Retinal energy demands control vascular supply of the retina in development and disease: the role of neuronal lipid and glucose metabolism","volume":"64","author":"Joyal","year":"2018","journal-title":"Prog Retin Eye Res"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.3390\/ijms22073689","article-title":"Energy metabolism in the inner retina in health and glaucoma","volume":"22","author":"Liu","year":"2021","journal-title":"Int J Mol Sci"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.preteyeres.2015.08.001","article-title":"The progress in understanding and treatment of diabetic retinopathy","volume":"51","author":"Stitt","year":"2016","journal-title":"Prog Retin Eye Res"},{"key":"bib6","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s00417-017-3711-0","article-title":"Hypoxia and inflammation in the release of VEGF and interleukins from human retinal pigment epithelial cells","volume":"255","author":"Arjamaa","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/978-3-030-66014-7","article-title":"Bruch's membrane and the choroid in age-related macular degeneration","volume":"1256","author":"Edwards","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1016\/j.ophtha.2016.04.056","article-title":"Anti-vascular endothelial growth factor agents in the treatment of retinal disease: from bench to bedside","volume":"123","author":"Campochiaro","year":"2016","journal-title":"Ophthalmology"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.preteyeres.2018.10.006","article-title":"The role of placental growth factor (PlGF) and its receptor system in retinal vascular diseases","volume":"69","author":"Van Bergen","year":"2019","journal-title":"Prog Retin Eye Res"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1016\/j.ophtha.2016.07.032","article-title":"Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies","volume":"123","author":"Heier","year":"2016","journal-title":"Ophthalmology"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"e0233595","DOI":"10.1371\/journal.pone.0233595","article-title":"Effectiveness and safety of ranibizumab 0.5 mg in treatment-na\u00efve patients with diabetic macular edema: results from the real-world global LUMINOUS study","volume":"15","author":"Mitchell","year":"2020","journal-title":"PLoS One"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ajo.2022.01.004","article-title":"KESTREL and KITE: 52-week results from two phase III pivotal trials of brolucizumab for diabetic macular edema","volume":"238","author":"Brown","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"bib14","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/j.ophtha.2012.05.017","article-title":"Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials","volume":"119","author":"Varma","year":"2012","journal-title":"Ophthalmology"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1177\/1947601911423654","article-title":"Hypoxia-induced angiogenesis: good and evil","volume":"2","author":"Krock","year":"2011","journal-title":"Genes Cancer"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","article-title":"Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data","volume":"35","author":"Joussen","year":"2021","journal-title":"Eye (Lond)"},{"key":"bib20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1126\/science.277.5322.55","article-title":"Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis","volume":"277","author":"Maisonpierre","year":"1997","journal-title":"Science"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/ncb1715","article-title":"Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts","volume":"10","author":"Saharinen","year":"2008","journal-title":"Nat Cell Biol"},{"key":"bib22","doi-asserted-by":"publisher","first-page":"11205","DOI":"10.1073\/pnas.172161899","article-title":"Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo","volume":"99","author":"Lobov","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"bib23","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.15252\/emmm.201505889","article-title":"Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases","volume":"8","author":"Regula","year":"2016","journal-title":"EMBO Mol Med"},{"key":"bib24","doi-asserted-by":"publisher","first-page":"a006550","DOI":"10.1101\/cshperspect.a006650","article-title":"The complex role of angiopoietin-2 in the angiopoietin-tie signaling pathway","volume":"2","author":"Thurston","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.19082\/5031","article-title":"Role of angiopoietins and Tie-2 in diabetic retinopathy","volume":"9","author":"Khalaf","year":"2017","journal-title":"Electron Physician"},{"key":"bib27","doi-asserted-by":"publisher","first-page":"17946","DOI":"10.1038\/srep17946","article-title":"Aflibercept traps Galectin-1, an angiogenic factor associated with diabetic retinopathy","volume":"5","author":"Kanda","year":"2015","journal-title":"Sci Rep"},{"key":"bib28","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.1172\/JCI74527","article-title":"Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature","volume":"124","author":"Shen","year":"2014","journal-title":"J Clin Invest"},{"key":"bib29","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1158\/1078-0432.CCR-15-1221","article-title":"A phase I first-in-human study of nesvacumab (REGN910), a fully human anti-angiopoietin-2 (Ang2) monoclonal antibody, in patients with advanced solid tumors","volume":"22","author":"Papadopoulos","year":"2016","journal-title":"Clin Cancer Res"},{"key":"bib33","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1080\/19420862.2016.1197457","article-title":"The use of CrossMAb technology for the generation of bi- and multispecific antibodies","volume":"8","author":"Klein","year":"2016","journal-title":"MAbs"},{"key":"bib34","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"bib35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1167\/tvst.11.10.36","article-title":"Evaluation of molecular properties versus in vivo performance of aflibercept, brolucizumab, and ranibizumab in a retinal vascular hyperpermeability model","volume":"11","author":"Schubert","year":"2022","journal-title":"Transl Vis Sci Technol"},{"key":"bib36","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J Roy Statist Soc Ser B (Methodol)"},{"key":"bib37","doi-asserted-by":"publisher","first-page":"D733","DOI":"10.1093\/nar\/gkv1189","article-title":"Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation","volume":"44","author":"O'Leary","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"bib38","doi-asserted-by":"publisher","first-page":"15419","DOI":"10.1038\/s41598-019-51633-8","article-title":"Characterisation of the inflammatory cytokine and growth factor profile in a rabbit model of proliferative vitreoretinopathy","volume":"9","author":"Wong","year":"2019","journal-title":"Sci Rep"},{"key":"bib39","doi-asserted-by":"publisher","first-page":"e70459","DOI":"10.1371\/journal.pone.0070459","article-title":"Angiopoietin-2 is critical for cytokine-induced vascular leakage","volume":"8","author":"Benest","year":"2013","journal-title":"PLoS One"},{"key":"bib40","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1126\/science.2479987","article-title":"Vascular permeability factor, an endothelial cell mitogen related to PDGF","volume":"246","author":"Keck","year":"1989","journal-title":"Science"},{"key":"bib41","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"bib42","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/jamaophthalmol.2020.2699","article-title":"Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase 2 randomized clinical trial","volume":"138","author":"Khanani","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"bib43","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1001\/jamaophthalmol.2020.2685","article-title":"Safety and efficacy of different doses and regimens of faricimab vs ranibizumab in neovascular age-related macular degeneration: the AVENUE phase 2 randomized clinical trial","volume":"138","author":"Sahni","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"bib44","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","article-title":"Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial","volume":"126","author":"Sahni","year":"2019","journal-title":"Ophthalmology"},{"key":"bib45","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1097\/IAE.0000000000003128","article-title":"Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration: the ARIES study: a randomized clinical trial","volume":"41","author":"Mitchell","year":"2021","journal-title":"Retina"},{"key":"bib46","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/j.ophtha.2014.05.009","article-title":"Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration","volume":"121","author":"Ho","year":"2014","journal-title":"Ophthalmology"},{"key":"bib47","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.omtn.2019.07.018","article-title":"Anti-angiogenic and anti-scarring dual action of an anti-fibroblast growth factor 2 aptamer in animal models of retinal disease","volume":"17","author":"Matsuda","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"bib48","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1172\/JCI31030","article-title":"Fibrosis and diseases of the eye","volume":"117","author":"Friedlander","year":"2007","journal-title":"J Clin Invest"},{"key":"bib49","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1167\/iovs.13-12978","article-title":"Systemic upregulation of PDGF-B in patients with neovascular AMD","volume":"55","author":"Zehetner","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib50","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ophtha.2019.09.021","article-title":"Intravitreal combined aflibercept + anti-platelet-derived growth factor receptor beta for neovascular age-related macular degeneration: results of the phase 2 CAPELLA trial","volume":"127","author":"Heier","year":"2020","journal-title":"Ophthalmology"},{"key":"bib52","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ophtha.2016.10.010","article-title":"Dual antagonism of PDGF and VEGF in neovascular age-related macular degeneration: a phase IIb, multicenter, randomized controlled trial","volume":"124","author":"Jaffe","year":"2017","journal-title":"Ophthalmology"},{"key":"bib53","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1167\/iovs.09-4006","article-title":"Identification of genes and pathways involved in retinal neovascularization by microarray analysis of two animal models of retinal angiogenesis","volume":"51","author":"Recchia","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib54","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/S0006-8993(00)03152-8","article-title":"ATP-sensitive potassium channels (K(ATP)) in retina: a key role for delayed ischemic tolerance","volume":"890","author":"Ettaiche","year":"2001","journal-title":"Brain Res"},{"key":"bib55","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41390-019-0598-y","article-title":"Short- and long-term impact of hyperoxia on the blood and retinal cells\u2019 transcriptome in a mouse model of oxygen-induced retinopathy","volume":"87","author":"Zasada","year":"2020","journal-title":"Pediatr Res"},{"key":"bib56","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.3390\/cancers12061363","article-title":"ESM-1 overexpression is involved in increased tumorigenesis of radiotherapy-resistant breast cancer cells","volume":"12","author":"Jin","year":"2020","journal-title":"Cancers (Basel)"},{"key":"bib57","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1371\/journal.pmed.0030113","article-title":"Angiopoietin-2: modulator of vascular permeability in acute lung injury?","volume":"3","author":"Hashimoto","year":"2006","journal-title":"PLoS Med"},{"key":"bib58","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.bbrc.2014.08.096","article-title":"miRNA-dependent cross-talk between VEGF and Ang-2 in hypoxia-induced microvascular dysfunction","volume":"452","author":"Zhao","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"bib16","article-title":"Lucentis prescribing information","author":"Genentech"},{"key":"bib17","article-title":"Beovu (brolucizumab-dbll) injection, for intravitreal injection","author":"Novartis"},{"key":"bib26","article-title":"Aflibercept (Eylea) summary of product characteristics","author":"Regeneron"},{"key":"bib30","article-title":"Anti-angiOpoeitin 2 plus anti-vascular eNdothelial growth factor as a therapY for neovascular age related macular degeneration: evaluation of a fiXed combination intravitreal injection (ONYX)","author":"ClinicalTrials.gov"},{"key":"bib31","article-title":"Anti-vasculaR endothelial growth factor plUs Anti-angiopoietin 2 in fixed comBination therapY: evaluation for the treatment of diabetic macular edema (RUBY)","author":"ClinicalTrials.gov"},{"key":"bib32","article-title":"Faricimab (VABYSMO) prescribing information","author":"Novartis\/Roche"},{"key":"bib51","article-title":"A phase 3 safety and efficacy study of Fovista (E10030) intravitreous administration in combination with lucentis compared to lucentis monotherapy","author":"ClinicalTrials.gov"}],"container-title":["Translational Vision Science & Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2785623","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T13:37:09Z","timestamp":1729431429000},"score":1,"resource":{"primary":{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2785623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5,1]]}},"URL":"https:\/\/doi.org\/10.1167\/tvst.12.5.17","relation":{},"ISSN":["2164-2591"],"issn-type":[{"value":"2164-2591","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,23]]}}}